Thrombin stimulates vascular smooth muscle cell polyamine synthesis by inducing cationic amino acid transporter and ornithine decarboxylase gene expression

Circ Res. 1998 Jul 27;83(2):217-23. doi: 10.1161/01.res.83.2.217.

Abstract

Thrombin, a serine protease, is a potent mitogen for vascular smooth muscle cells (SMCs), but its mechanism of action is not known. Since L-ornithine is metabolized to growth-stimulatory polyamines, we examined whether thrombin regulates the transcellular transport and metabolism of L-ornithine by vascular SMCs. Treatment of SMCs with thrombin initially (0 to 2 hours) decreased L-ornithine uptake, whereas longer exposures (6 to 24 hours) progressively increased transport. Kinetic studies indicated that thrombin-induced inhibition was associated with a decrease in affinity for L-ornithine, whereas stimulation was mediated by an increase in transport capacity. Thrombin induced the expression of both cationic amino acid transporter (CAT)-1 and CAT-2 mRNA. Furthermore, thrombin stimulated L-ornithine metabolism by inducing ornithine decarboxylase (ODC) mRNA expression and activity. The stimulatory effect of thrombin on both L-ornithine transport and ODC activity was reversed by hirudin, a thrombin inhibitor, and was mimicked by a 14-amino acid thrombin receptor-activating peptide. Thrombin also markedly increased the capacity of SMCs to generate putrescine, a polyamine, from extracellular L-ornithine. The thrombin-mediated increase in putrescine production was reversed by N(G)-methyl-L-arginine, a competitive inhibitor of cationic amino acid transport, or by alpha-difluoromethylornithine (DFMO), an ODC inhibitor. DFMO also inhibited thrombin-induced SMC proliferation. These results demonstrate that thrombin stimulates polyamine synthesis by inducing CAT and ODC gene expression and that thrombin-stimulated SMC proliferation is dependent on polyamine formation. The ability of thrombin to upregulate L-ornithine transport and direct its metabolism to growth-stimulatory polyamines may contribute to postangioplasty restenosis and atherosclerotic lesion formation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amino Acid Transport Systems, Basic
  • Animals
  • Aorta, Thoracic / cytology
  • Biological Transport
  • Carrier Proteins / biosynthesis*
  • Carrier Proteins / genetics
  • Cell Division / drug effects
  • Cells, Cultured
  • Eflornithine / pharmacology
  • Enzyme Induction / drug effects
  • Enzyme Inhibitors / pharmacology
  • Gene Expression Regulation / drug effects*
  • Male
  • Membrane Proteins / biosynthesis*
  • Membrane Proteins / genetics
  • Muscle Proteins / biosynthesis*
  • Muscle Proteins / genetics
  • Muscle, Smooth, Vascular / drug effects*
  • Muscle, Smooth, Vascular / metabolism
  • Ornithine / metabolism
  • Ornithine Decarboxylase / biosynthesis*
  • Ornithine Decarboxylase / genetics
  • Ornithine Decarboxylase Inhibitors
  • Polyamines / metabolism*
  • Putrescine / biosynthesis
  • RNA, Messenger / biosynthesis
  • Rats
  • Thrombin / pharmacology*
  • omega-N-Methylarginine / pharmacology

Substances

  • Amino Acid Transport Systems, Basic
  • Carrier Proteins
  • Enzyme Inhibitors
  • Membrane Proteins
  • Muscle Proteins
  • Ornithine Decarboxylase Inhibitors
  • Polyamines
  • RNA, Messenger
  • omega-N-Methylarginine
  • Ornithine
  • Thrombin
  • Ornithine Decarboxylase
  • Putrescine
  • Eflornithine